Development of p62-Keap1 protein–protein interaction inhibitors as doxorubicin-sensitizers against non-small cell lung cancer

Development of p62-Keap1 protein–protein interaction inhibitors as doxorubicin-sensitizers against non-small cell lung cancer

Aberrant hyperactivation of nuclear factor erythroid 2-related factor 2 (Nrf2) has been reported in non-small cell lung cancer through overexpression of the p62/sequestosome1 protein, resulting in the acquisition of malignancy and drug resistance. We previously discovered compounds termed K67 and KO...

Full description

Bibliographic Details
Main Authors: Daisuke Yasuda, Ippei Yoshida, Riyo Imamura, Daiki Katagishi, Kyoko Takahashi, Hirotatsu Kojima, Takayoshi Okabe, Yoshinobu Ichimura, Masaaki Komatsu, Tadahiko Mashino, Tomoyuki Ohe
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Results in Chemistry
Subjects:
Nrf2
Keap1
p62
Doxorubicin
NSCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S2211715622003289

Internet

http://www.sciencedirect.com/science/article/pii/S2211715622003289

Similar Items